UBS has issued new research reports this week and has identified two companies with market-moving news they think are worth a look.
The company's seed technologies division was expected to deliver strong growth, led by growth in hybrid seeds and improved omega-3 pricing.
UBS said the expected result was a 2%-3% downgrade to previous expectations.
UBS has a price target of $22 on Telix shares compared to the current price of $16.01.
4 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Summarized version
Nufarm Ltd Nufarm shares are up by more than a third over the past 12 months, but UBS believes the stock still has a way to run.
Headline check
Two of the three things this headline claims did not turn up in the report.
The figure “13%” is in the headline. We could not find it in the report.
The figure “37%” is in the headline. We could not find it in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. Figures are matched digit for digit, so a report that writes “forty per cent” out in words where the headline wrote “40%” is queried here when it should not be. How this is checked
library pictureNot from this story. A library photograph of
stock market trading screens, used to illustrate it.
Manns' superior seeds (15767599714)
Henry G. Gilbert Nursery and Seed Trade Catalog Collection.; J. Manns & Co. / Wikimedia Commons, CC BY
The article, shortened and in plain language
UBS has issued new research reports this week and has identified two companies with market-moving news they think are worth a look.
Nufarm shares are up by more than a third over the past 12 months but UBS believes the stock still has a way to run.
The company this week put out new earnings guidance.
The company's seed technologies division was expected to deliver strong growth, led by growth in hybrid seeds and improved omega-3 pricing.
On the negative side of the ledger Nufarm said it expected to book $90-$110 million in write downs.
UBS said the expected result was a 2%-3% downgrade to previous expectations.
The broker has a price target of $3.50 on Nufarm shares compared to $3.12 now.
UBS has a price target on Telix after attending a R&D day which the broker said, "showcased the meaningful clinical development for TLX's diagnostics and therapeutics pipeline across prostate, brain, and kidney cancers''."
UBS has a price target of $22 on Telix shares compared to the current price of $16.01.
Shortened to 1 minute
of reading, this version reads 5.4 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How outlets headlined it
Each outlet's own headline. Struck through: the loaded words our version leaves out. Plainest first.
The Motley Fool Australia2 ASX shares UBS says could increase 13% to 37%plain
The Motley Fool AustraliaEOS shares jump 7% as ASX 200 falls. Could $15 be next?plain
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works
